The Managed Care Review Board™ Analysis of Treatments for Multiple Sclerosis — Web Activity

TARGET AUDIENCE

 

DISTINGUISHED FACULTY
Jeffrey D. Dunn, PharmD, MBA
Senior Vice President
VRx Pharmacy Services, LLC

Click here for biography
John Fox, MD, MHA
Senior Medical Director
Associate Vice President, Medical Affairs
Priority Health

Click here for biography
Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine

Click here for biography
Fadia T. Shaya, PhD, MPH
Professor and Vice-Chair for Academic Affairs
Director of Research, CIPS
University of Maryland School of Pharmacy

Click here for biography

STATEMENT OF NEED/PROGRAM OVERVIEW

Due to the large volume of patients they manage, managed care professionals are in an excellent position to improve outcomes for patients with MS.  There is a documented need to provide the managed care community with insights from notable clinical and managed care experts regarding the treatment of patients with MS and the evolving role of managed care.  Neurology and managed care thought leaders will evaluate and recommend innovative strategies that will increase knowledge and competence of the target audience as they strive to improve treatment outcomes for MS patients.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

ACCREDITATION

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC.  The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0809-9999-15-036-H01-P, Application

Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

Nursing Continuing Education
Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter Reported Financial Relationship
Jeffrey D. Dunn, PharmD, MBA Consulting Fees: Biogen Idec, Genzyme, a Sanofi Company, Teva Pharmaceutical Industries
John Fox, MD, MHA No financial interest/relationships relating to the topic of this activity
Fred D. Lublin, MD Consulting Fees: Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, Inc., Novartis, Teva Neuroscience, Actelion, Sanofi-Aventis, Acorda, Questcor, Roche, Genentech, Celgene, Johnson & Johnson, Revalesio, Coronado Bioscience, Genzyme, MedImmune, Bristol-Myers Squibb, Xenoport, Receptos, Forward Pharma, to-BBB technologies

Research Funding: Acorda Therapeutics, Inc., Biogen Idec, Novartis Pharmaceuticals Corp., Teva Neuroscience, Inc., Genzyme, Sanofi, Celgene, Transparency Life Sciences, National Institute of Health, National Multiple Sclerosis Society

Speaker (non-promotional): Genzyme

Financial Interest: Cognition Pharmaceuticals, Inc.
Fadia T. Shaya, PhD, MPH No financial interest/relationships relating to the topic of this activity

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Content Manager Reported Financial Relationship
Steven Casebeer, MBA No financial interest/relationships relating to the topic of this activity
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period March 1, 2015 through September 30, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.